NCT07285395 2025-12-16
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
Clinical Trials
27 trialsNCT03191682 2025-09-25
A First-in-Human Study of PRL3-ZUMAB
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT07101549 2025-08-03
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1 Not yet recruiting
NCT06719362 2025-07-10
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
Phase 1 Recruiting
NCT06954558 2025-05-01
GUARDIAN
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Recruiting
NCT06801470 2025-02-07
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
Phase 1 Recruiting
NCT03387917 2024-12-02
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Swiss Cancer Institute
Phase 1 Terminated
NCT06329206 2024-07-08
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
Phase 1 Recruiting
NCT06134531 2023-11-18
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
Nanfang Hospital, Southern Medical University
Phase 1 Not yet recruiting
NCT05976906 2023-08-04
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
Zhejiang University
Phase 1 Unknown
NCT05972460 2023-08-02
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT05942378 2023-07-12
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
Fudan University
Phase 1 Unknown
NCT04601285 2023-07-06
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT05502393 2022-08-16
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT03415659 2020-02-17
Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
Phase 1 Unknown
NCT02614456 2019-11-29
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Fox Chase Cancer Center
Phase 1 Completed
NCT03320525 2018-10-02
CHITIN
Herlev Hospital
Phase 1 Terminated
NCT01497626 2016-02-17
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
Phase 1 Terminated
NCT01128998 2015-10-19
Sorafenib Plus S-1 in Advanced Solid Tumors
National Health Research Institutes, Taiwan
Phase 1 Completed
NCT00951158 2015-05-12
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Terminated
NCT01170871 2014-05-21
Ixabepilone and Pemetrexed/Solid Tumors
University of Southern California
Phase 1 Withdrawn
NCT01050985 2014-02-13
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Georgetown University
Phase 1 Completed
NCT01055795 2012-12-24
BEL
Duke University
Phase 1 Completed
NCT01521299 2012-08-28
A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn
NCT01155505 2011-09-13
Lenalidomide and Paclitaxel in Advanced Solid Tumors
Southern Europe New Drug Organization
Phase 1 Unknown
NCT01159418 2011-09-13
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
Southern Europe New Drug Organization
Phase 1 Unknown
NCT01220284 2010-10-13
Satraplatin and Vinorelbine in Advanced Solid Tumors
Southern Europe New Drug Organization
Phase 1 Unknown